JG
EDIT icon

Jefferies Group’s Editas Medicine EDIT Stock Holding History

Jefferies Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$673K Hold
55,000
– – 0.01% 934
2022
Q2 		$651K Buy
55,000
+6,600
+14% +$88.4K 0.01% 921
2022
Q1 		$921K Buy
+48,400
New +$900K 0.01% 904

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jefferies Group's EDIT Position: Q3 2022 in Review

Jefferies Group increased its Editas Medicine (EDIT) stake by 116% in Q3 2022, buying an estimated $1.43M and bringing the position to 170,142 shares worth $2.08M. The position accounts for 0.02% of the portfolio, ranked #592.

Jefferies Group first reported a position in EDIT in Q4 2019 and has held it in 8 quarters since. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Jefferies Group held 170,142 shares of Editas Medicine worth $2.08M as of Q3 2022.
  • Jefferies Group bought 91,552 Editas Medicine shares in Q3 2022, an estimated $1.43M.
  • Editas Medicine made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #592 holding.
  • Jefferies Group first reported a position in Editas Medicine in Q4 2019 and has held it in 8 quarters since.
  • 264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.